重定向溶瘤病毒经工程化改造以重塑肿瘤微环境用于胶质母细胞瘤免疫治疗

Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy.

胶质瘤中的 NK 细胞功能障碍：从免疫逃逸到免疫治疗

Natural killer cell dysfunction in glioma: from immune evasion to immunotherapy.

利用表达西妥昔单抗-CCL5 融合蛋白的溶瘤病毒通过固有免疫和适应性免疫特异性靶向胶质母细胞瘤

Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity.

胶质母细胞瘤中的信号通路失调与治疗耐药：分子机制与新兴治疗靶点

Pathway dysregulation and therapeutic resistance in glioblastoma: molecular mechanisms and emerging therapeutic targets.

儿童脑肿瘤的局部区域和全身过继性细胞疗法：CAR-T、TCR 工程 T 细胞和 NK 细胞策略的系统综述

Locoregional and systemic adoptive cellular therapies for pediatric brain tumors: a systematic review of CAR‑T, TCR‑engineered T cells, and NK cell st

体外评估基因未修饰的配体武装异体 NK 细胞治疗 EGFR 阳性胶质母细胞瘤

In Vitro Evaluation of Genetically Unmodified Ligand-Armed Allogeneic Natural Killer Cells to Treat EGFR-Positive Glioblastoma.

针对多形性胶质母细胞瘤的 NK 细胞免疫治疗潜在分子靶点

Prospective Molecular Targets for Natural Killer Cell Immunotherapy against Glioblastoma Multiforme.

革新胶质母细胞瘤治疗：现代治疗方法的全面概述

Revolutionizing Glioblastoma Treatment: A Comprehensive Overview of Modern Therapeutic Approaches.

双靶向胶质母细胞瘤细胞的双特异性杀伤细胞衔接器靶向 EGFR 和 ErbB2（HER2）促进 NKG2D-CAR 工程化 NK 细胞的有效清除

Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D

细胞因子在体外影响 NK 细胞对胶质母细胞瘤的表型和功能

Cytokines impact natural killer cell phenotype and functionality against glioblastoma in vitro.

根据我们的研究结果，NK 细胞的体外扩增能力和功能受多种因素影响，如供者、起始材料的组成、细胞因子组合和激活方案。细胞因子改变了 NK 细胞的表型和功能，这在其对胶质瘤细胞系的反应性中表现明显。据我们所知，这是首次进行如此程度的全面比较研究，这些发现可用于扩大临床 NK 细胞生产规模。